Navigation Links
Data Presented at AACR Annual Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Tumor Growth By Up to 95% and Halts Metastasis in a Model of Hormone-Refractory Prostate Cancer
Date:4/15/2008

pril 14, 2008, 2:10 PM - 2:25 PM

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that results from future preclinical studies and clinical trials will not correlate with the results of these preclinical studies, the risk that bavituximab will not provide comparable results in combination with other cancer therapies and the risk that the Company will experience delays in enrolling patients in its existing and planned clinical studies. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologi
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrines anti-PS Vascular Targeting Antibodies
2. Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
3. PG500 Series Presented at the AACR Annual Meeting in San Diego
4. Research Presented at ISHLT Shows Promise of Addressing Critical Organ Shortage and Better Organ Preservation
5. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
6. Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings
7. Senescos Preclinical Pancreatic Islet Data to be Presented at Upcoming Conferences
8. Genaera Corporation Announces MSI-1436 Data Presented at Society of Neuroscience Meeting
9. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
10. New Trial Presented at AAAAI Reports that the Growth of Children 2-5 Years Old with Year-Round Allergic Rhinitis Continued According to Normal Age-Adjusted Distribution Over a 6-Month Treatment with Nasacort AQ
11. New Clinical Studies Presented at the 14th World Congress of Anesthesiology Demonstrate Masimo Advancements in Patient Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2008)... - Clinical trial currently in Phase I -, .../ -- Tobira,Therapeutics Inc., a clinical stage bi...product discovery against life-threatening and lif...e issuance of Patent No. 7,371,772,B2 by the U.S. ...BR-652, a,CCR5 antagonist currently in Phase I dev...
(Date:8/17/2008)..., Australia, Aug. 17 /Xinhua-PRNewswire-FirstCall/...nced that the first pivotal Phase 3,clinical trial...s has,completed enrolment., The first efficacy da...ng the first half of 2009. The trial commenced its...ecruitment target of 250 subjects in June,2008 and...
(Date:8/14/2008)...ORE, Aug. 15 /- AstraZeneca...artnership with the National Cancer,Centre Singapo...H) to,develop anti-cancer compounds. The collabora...tanding (MOU) that was signed today, aims to furth...es in Asia and ultimately,speed up access to new m...
(Date:8/14/2008)...TON, N.J., Aug. 14 /- Pharm...rmaceutical company committed to,discovering, deve...ral,infections, reported unaudited financial resul...8. Pharmasset reported a net loss attributable to,...r share of $0.69 for the,quarter ended June 30, 20...
Breaking Medicine Technology:Bronchitol Phase 3 Cystic Fibrosis Trial Completes Recruitment 2AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds 2AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds 3AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds 4AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds 5AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds 6Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 2Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 3Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 4Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 5Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 6Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 7Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 8Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 9Amylin Pharmaceuticals to Present at FBR Capital Markets Investor Conference 5596 1New CDC Study Shows Smoke Free Laws Spreading Across U S and Should Spur Remaining States to Take Action 20109 1New CDC Study Shows Smoke Free Laws Spreading Across U S and Should Spur Remaining States to Take Action 20109 2New CDC Study Shows Smoke Free Laws Spreading Across U S and Should Spur Remaining States to Take Action 20109 3Pioneer 28R 29 Surgical Technology Introduces the BacJac 28TM 29 Interspinous Decompression System to the European Spine Market 20104 1Pioneer 28R 29 Surgical Technology Introduces the BacJac 28TM 29 Interspinous Decompression System to the European Spine Market 20104 2Major missed biochemical pathway emerges as important in virtually all cells 20103 1Major missed biochemical pathway emerges as important in virtually all cells 20103 2Major missed biochemical pathway emerges as important in virtually all cells 20103 3
...and Drug Administration,(FDA) is aware of a potent...), a drug approved to treat type 2 diabetes. Safet...that there is a,potentially significant increase i...s in patients taking Avandia. However, other,publi...trials of,Avandia, including an interim analysis o...
.../ -- Wyeth (NYSE: WYE),today announced that the U....istrict Office has informed the Company that the r...o manufacturing,facility has resulted in a positiv...cation means that any issues found by the FDA have...rit any further,regulatory action. Guayama will co...
Other Medicine Technology:FDA Issues Safety Alert on Avandia 2FDA Issues Safety Alert on Avandia 3FDA Re-Inspection Results in Positive Re-Classification of Guayama,Facility 2FDA Re-Inspection Results in Positive Re-Classification of Guayama,Facility 3
(Date:8/20/2008)...r-old Contestant Wins Trip to Little League Baseba... The National Spit Tobacco Education,Program (NSTE...st today,and encouraged young baseball players to...ddiction and the health risks of using tobacco pro...year,s slogan contest winner is,Joe Reck, a nine-y...
(Date:8/20/2008)...cently enacted Medicare Improvement Law immediatel...re Advantage insurance companies .../PRNewswire/ -- When the House and Senate,overrode...gislation,protecting Medicare beneficiaries, they ...e Advantage plans during one of the busiest months...
(Date:8/20/2008)...T CREEK, Calif., Aug. 20 /PRNewswire-FirstCall/ --... reported preliminary income from,continuing opera...f $27.5,million, or $0.76 per diluted share, inclu...er diluted share, related to provisions for store,... a 6.8 percent increase,compared with income from ...
(Date:8/20/2008)...FIELD, Mich., Aug. 20 /PRNewswire/ -- WXYZ- TV/Cha...llness Promotion will give thousands of,Detroit me...ALTHY LIVING,FOR KIDS" program. This year the prog....m. to 5 p.m. at the Charles H. Wright Museum of A...77, "Healthy Living for Kids",has provided free im...
Breaking Medicine News(10 mins):Health News:Slogan Contest Educates Young Baseball Players About the Dangers of Tobacco Use 2Health News:Medicare Advantage Plans Struggle to Comply With New Federal Law 2Health News:Longs Drug Stores Corporation Reports Second Quarter Results 2Health News:Longs Drug Stores Corporation Reports Second Quarter Results 3Health News:Longs Drug Stores Corporation Reports Second Quarter Results 4Health News:Longs Drug Stores Corporation Reports Second Quarter Results 5Health News:Longs Drug Stores Corporation Reports Second Quarter Results 6Health News:Longs Drug Stores Corporation Reports Second Quarter Results 7Health News:Longs Drug Stores Corporation Reports Second Quarter Results 8Health News:Longs Drug Stores Corporation Reports Second Quarter Results 9Health News:Longs Drug Stores Corporation Reports Second Quarter Results 10Health News:Longs Drug Stores Corporation Reports Second Quarter Results 11Health News:Longs Drug Stores Corporation Reports Second Quarter Results 12Health News:Longs Drug Stores Corporation Reports Second Quarter Results 13Health News:WXYZ-TV/Channel 7 is 'On Your Side' With Healthy Living For Kids; Free Immunizations for Children on Sunday, August 24 at Charles H. Wright Museum of African American History 2Health News:WXYZ-TV/Channel 7 is 'On Your Side' With Healthy Living For Kids; Free Immunizations for Children on Sunday, August 24 at Charles H. Wright Museum of African American History 3
...been extended to 2015. The commission had been as...ness as well as advocating for the needs of the me...996 it was set up in response to the Mason Inquiry...y were helpful in developing a blueprint for impro...
...d none other than ‘gen–present’ and ‘gen-next’ can...s the ebb and flow of waters continue unabated, pe...e no tomorrows. Living on the edge, seeking newer ...ure-postcard’ life is the present age magnificent ...
...ducted a voluntary recall of over 5,000 lbs. of gr...t consumers //of probable beef contamination that ...rday morning President Jim Goeser said, "We should...n the beef in question from a certified lab but th...
...Sunday the first death caused by dengue fever in A...ted// from different parts of the state. Venkates...the death of the person from Puttaparthi in Ananta...e in Khammam and one in Srikakulam districts are c...
Other Medicine News:Health News:Mental Health: Mind at Peace or in Pieces? 2Health News:Mental Health: Mind at Peace or in Pieces? 3Health News:Mental Health: Mind at Peace or in Pieces? 4Health News:Precautionary Recall of Beef over E.coli Contamination Concerns 2Health News:First confirmed Dengue death in Andhra Pradesh 2
...feature full monochromatic and chromatic correctio...illiant, rich-contrast, completely flat images for...ed-light methods. Their high transmission of wavel...e of glass types of low autofluorescence makes the...
Inquire
Epiplan-Neofluar objectives is a series of objectives for the examination of materials. They differ from Epiplan objectives by their higher NA and, accordingly, higher resolving power. Unlike the Epi
...ransmission rate, especially in the ultraviolet, a...mat series, these objectives are designed for fluo...e of improved quality, these objectives can functi...orescence, polarising and DIC observations. The DL...
Medicine Products: